四价登革热疫苗(TAK-003)在有既往日本脑炎或黄热病疫苗接种史儿童中的有效性和安全性
研究纳入20071名4-16岁儿童,按2:1随机接种TAK-003或安慰剂。接种57个月后,TAK-003在有黄热病疫苗接种史者中有效性为55.7%,有日本脑炎疫苗接种史者为77.8%,无既往黄热病/日本脑炎疫苗接种史者为53.5%;数据未提示既往日本脑炎或黄热病疫苗接种对TAK-003性能有临床相关影响。
要点
- 有日本脑炎疫苗接种史儿童中TAK-003有效性为77.8%,无既往黄热病/日本脑炎疫苗接种史者为53.5%。
- 有黄热病疫苗接种史儿童中TAK-003有效性为55.7%。
- 日本脑炎疫苗接种亚组中较高的表观有效性很大程度上可由TAK-003的血清型特异性有效性解释。
核心结论
- 现有数据未提示既往日本脑炎或黄热病疫苗接种对TAK-003性能有临床相关影响。
- 总体而言,TAK-003在不同流行病学环境中耐受性良好且有效。
研究设计与样本
- 4-16岁儿童按2:1随机接受TAK-003或安慰剂,并进行主动发热监测。
- 症状性登革热经血清型特异性逆转录聚合酶链反应确诊。
- 记录黄热病和日本脑炎疫苗接种史。
主要发现
- 接受TAK-003或安慰剂的20071名儿童中,随机化时有黄热病疫苗接种史者占21.1%,有日本脑炎疫苗接种史者占23.9%。
- 接种57个月后,有黄热病疫苗接种史者中疫苗有效性为55.7%(95%CI 39.7%-67.5%)。
- 有日本脑炎疫苗接种史者中疫苗有效性为77.8%(95%CI 70.8%-83.1%)。
- 无既往黄热病/日本脑炎疫苗接种史者中疫苗有效性为53.5%(95%CI 45.4%-60.4%)。
- 血清型分布的地区差异混杂了这些结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 血清型分布的地区差异混杂了这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We explored the impact of prior yellow fever (YF) or Japanese encephalitis (JE) vaccination on the efficacy of Takeda's dengue vaccine candidate, TAK-003. METHODS: Children 4-16 years of age were randomized 2:1 to receive TAK-003 or placebo and were under active febrile surveillance. Symptomatic dengue was confirmed by serotype-specific reverse-transcription polymerase chain reaction. YF and JE vaccination history was recorded. RESULTS: Of the 20 071 children who received TAK-003 or placebo, 21.1% had a YF and 23.9% had a JE vaccination history at randomization. Fifty-seven months after vaccination, vaccine efficacy (95% confidence interval) was 55.7% (39.7%-67.5%) in those with YF vaccination, 77.8% (70.8%-83.1%) for JE vaccination, and 53.5% (45.4%-60.4%) for no prior YF/JE vaccination. Regional differences in serotype distribution confound these results. The apparent higher vaccine efficacy in the JE vaccination subgroup could be largely explained by serotype-specific efficacy of TAK-003. Within 28 days of any vaccination, the proportions of participants with serious adverse events in the YF/JE prior vaccination population were comparable between the TAK-003 and placebo groups. CONCLUSIONS: The available data do not suggest a clinically relevant impact of prior JE or YF vaccination on TAK-003 performance. Overall, TAK-003 was well-tolerated and efficacious in different epidemiological settings. Clinical Trials Registration. NCT02747927.
引用
- Sirivichayakul C, Biswal S, Saez-Llorens X, et al. Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination. J Infect Dis. 2024. PMID: 38682569. doi:10.1093/infdis/jiae222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。